Ankara Üniversitesi Veteriner Fakültesi Dergisi
Araştırma Makalesi
PDF EndNote BibTex RIS Kaynak Göster

Yıl 2019, Cilt: 66 Sayı: 4, 343 - 350, 09.09.2019

Ender Deniz ASMAZ Berrin ZIK

https://doi.org/10.33988/auvfd.498411

Öz

Kaynakça

  • 1. Akduman AT, Özerkan K, Zik B, et al (2014): Effect of tamoxifen on ovarian reserve: A randomized controlled assessor-blind trial in a mouse model. J Turk Ger Gynecol Assoc, 15, 228-232.
  • 2. Akkaya OO, Altunbas K, Yagcı A (2017): Effects of methoxychlor on IGF-1 signaling pathway in rat ovary. Biotech Histochem, 92, 230-242.
  • 3. Armstrong DG, Gutierrez CG, Baxter G, et al (2000): Expression of mRNA encoding IGF-1, IGF-1I and type 1 IGF receptor in bovine ovarian follicles. J Endocrinol, 165, 101-113.
  • 4. Armstrong DG, Webb R (1997): Ovarian follicular dominance: the role of intraovarian growth factors and novel proteins. Rev Reprod, 2, 139–146.
  • 5. Baumgarten SC, Convissar SM, Fierro MA, et al (2014): IGF1R signaling is necessary for FSH-induced activation of AKT and differentiation of human cumulus granulosa cells. J Clin Endocrinol Metab, 99, 2995-3004.
  • 6. Cara JF, Rosenfield RL (1988): Insulin-like growth factor I and ınsulin potentiate luteinizing hormone-ınduced androgen synthesis by rat ovarian thecal-interstitial cells. Endocrinology, 123, 733-739.
  • 7. Cohen I, Figer A, Tepper R, et al (1999): Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen treated and nontreated breast cancer patients. Gynecol Oncol, 72, 202-207.
  • 8. Crossman G (1937): A modification of Mallory’s connective tissue stain with a discussion of the principles involved. Anat Rec, 69, 33-38.
  • 9. Cruickshank J, Grossman DI, Peng RK, et al (2005): Spatial distribution of growth hormone receptor, insulin-like growth factor-I receptor and apoptotic chondrocytes during growth plate development. J Endocrinol, 184, 543-553.
  • 10. Ergin K, Gursoy E, Baġımoğlu-Koca Y, et al (2008): Immunohistochemical detection of insulin-like growth factor-I, transforming growth factor-b2, basic fibroblast growth factor and epidermal growth factor-receptor expression in developing rat ovary. Cytokine, 43, 209-214.
  • 11. Fu Z, Noguchi T, Kato H (2001): Vitamin a deficiency reduces insulin-like growth factor (IGF)-I gene expression and increases IGF-1 receptor and insulin receptor gene expression in tissues of japanese quail (coturnix coturnix japonica). J Nutr, 131, 1189-1194.
  • 12. Guthrie HD, Garrett WM, Cooper BS (1998): Follicle-stimulating hormone and insulin-like growth factor-I attenuate apoptosis in cultured porcine granulosa cells. Biol Reprod, 58, 390-396.
  • 13. Higgins MJ, Baselga J (2011): Targeted therapies for breast cancer. J Clin Invest, 121, 3797-3803.
  • 14. Hu CL, Cowan RG, Harman RM, et al (2004): Cell cycle progression and activation of akt kinase are required for insulin-like growth factor I-mediated suppression of apoptosis in granulosa cells. Mol Endocrinol, 18, 326-338.
  • 15. Kwintkiewicz J, Giudice LC (2009): The interplay of insulin-like growth factors, gonadotropins, and endocrine disruptors in ovarian follicular development and function. Semin Reprod Med, 27, 43-51.
  • 16. Luigi LD, Conti FG, Casini A (1997): Growth hormone and insulin-like growth factor I responses to moderate submaximal acute physical exercise in man: effects of octreotide, a somatostatin analogue, administration. Int J Sports Med, 18, 257-263.
  • 17. Macgregor JI, Jordan C (1998): Basic guide to the mechanisms of antiestrogens. Pharmacol Rev, 50, 151-196.
  • 18. Mahran YF, El-Demerdash E, Nada AS, et al (2013): Insights into the protective mechanisms of tamoxifen in radiotherapy-induced ovarian follicular loss: Impact on insulin-like growth factor 1. Endocrinology, 154, 3888-3899.
  • 19. Mazerbourg S, Bondy CA, Zhou J, et al (2003): The insulin-like growth factor system: a key determinant role in the growth and selection of ovarian follicles? a comparative species study. Reprod Domest Anim, 38, 247-258.
  • 20. Monget P, Fabre S, Mulsant P, et al (2002): Regulation of ovarian folliculogenesis by IGF and BMP system in domestic animals. Domest Anim Endocrinol, 23, 139-154.
  • 21. Monniaux D, Pisselet C (1992): Control of proliferation and differentiation of ovine granulosa cells by insulin-like growth factor-I and follicle-stimulating hormone in vitro. Biol Reprod, 46, 109-119.
  • 22. Mourits MJE, Vries EGE, Willemse PHB, et al (1999): Ovarian cysts in women receiving tamoxifen for breast cancer. Br J Cancer, 79, 1761-1764.
  • 23. O'Regan RM, Cisneros A, England GM, et al (1998): Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. J Natl Cancer Inst, 90, 1552-1558.
  • 24. Pasqualini JR, Sumida C, Giambiagi N (1998): Pharmacodynamic and biological effects of anti-estrogens in different models. J Steroid Biochem, 31, 613-643.
  • 25. Perks CM, Peters AR, Wathes DC (1999): Follicular and luteal expression of insulin-like growth factors I and II and the type 1 IGF receptor in the bovine ovary. J Reprod Fertil, 116, 157-165.
  • 26. Pollak MN, Huynh HT, Lefebvre SP (1992): Tamoxifen reduces serum insulin-like growth factor I (IGF-1). Breast Cancer Res Treat, 22, 91-100.
  • 27. Qu J, Godin PA, Nisolle M, et al (2000): Expression of receptors for insulin-like growth factor-I and transforming growth factor-β in human follicles. Mol Hum Reprod, 6, 137-145.
  • 28. Quirk SM, Cowan RG, Harman RM, et al (2004): Ovarian follicular growth and atresia: the relationship between cell proliferation and survival. J Anim Sci, 82, 40-52.
  • 29. Ramachandran C, Khatib Z, Petkarou A, et al (2004): Tamoxifen modulation of etoposide cytotoxicity involves inhibition of protein kinase C activity and insulin-like growth factor II expression in brain tumor cells. J Neurooncol, 67, 19-28.
  • 30. Rzepczynska IJ, Piotrowski PC, Wong DH, et al (2009): Role of isoprenylation in Simvastatin-Induced inhibition of ovarian theca-interstitial growth in the rat. Biol Reprod, 81, 850-855.
  • 31. Sherman BM, Chapler FK, Crickard K, et al (1979): Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women. J Clin Invest, 64, 398-404.
  • 32. Shushan A, Peretz T, Uziely B, et al (1996): Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer. Am J Obstet Gynecol, 174, 141-144.
  • 33. Spicer LJ, Chamberlain CS (1998): Influence of cortisol on insulin- and insulin-like growth factor 1 (IGF-1)-induced steroid production and on IGF-1 receptors in cultured bovine granulosa cells and thecal cells. Endocrine, 9, 153-161.
  • 34. Terada S, Uchide K, Suzuki N (1993): A follicular cyst during tamoksifen therapy in a premenopausal breast cancer woman. Gynecol Obstet Invest, 35, 62-64.
  • 35. Thissen JP, Ketelslegers JM, Underwood LE (1994): Nutritional regulation of the insulin-like growth factors. Endocr Rev, 15, 80-163.
  • 36. Ting AY, Kimler BF, Fabian CJ, et al (2008): Tamoxifen prevents premalignant changes of breast but not ovarian cancer in rats at high risk for both diseases. Cancer Prev Res, (Phila) 1, 546-553.
  • 37. Ting AY, Petroff BK (2010): Tamoxifen decreases ovarian follicular loss from experimental toxicant DMBA and chemotherapy agents cyclophosphamide and doxorubicin in the rat. J Assist Reprod Genet, 27, 591-597.
  • 38. Toda K, Miyaura C, Okada T, et al (2002): Dietary bisphenol a prevents ovarian degeneration and bone loss in female mice lacking the aromatase gene (Cyp19). Eur J Biochem, 269, 2214-2222.
  • 39. Tsujioka S, Ban Y, Wise LD, et al (2009): Collaborative work on evaluation of ovarian toxicity. 3) Effects of 2- or 4- week repeated dose toxicity and fertility studies with tamoksifen in female rats. J Toxicol Sci, 34, 43-51.
  • 40. Tucker MJ, Adam HK, Patterson JS (1984): Tamoxifen. 125-161. In: DR Laurence, AEM McLean, M Wetherall (Eds), Safety Testing of New Drugs, Laboratory Predictions and Clinical Performance. Academic. Press, London.
  • 41. Wandji SA, Wood TL, Crawford J, et al (1998): Expression of mouse ovarian insulin growth factor system components during follicular development and atresia. Endocrinology, 139, 5205-5214.
  • 42. Werner H, Shen-Orr Z, Stannard B, et al (1990): Experimental diabetes ıncreases ınsulinlike growth factor I and II receptor concentration and gene expression in kidney. Diabetes, 39, 1490-1497.
  • 43. Zhou J, Chin E, Bondy C (1991): Cellular pattern of insulin-like factor-I (IGF-1) and IGF-1 receptor gene expression in the developing and mature ovarian follicle. Endocrinology, 129, 3281-3288.
  • 44. Zhou P, Baumgarten SC, Wu Y, et al (2013): IGF-1 signaling is essential for FSH stimulation of AKT and steroidogenic genes in granulosa cells. Mol Endocrinol, 27, 511-523.

The effect of tamoxifen on IGF signaling pathway in the mouse ovary

Yıl 2019, Cilt: 66 Sayı: 4, 343 - 350, 09.09.2019

Ender Deniz ASMAZ Berrin ZIK

https://doi.org/10.33988/auvfd.498411

Öz

Tamoxifen (TAM) is one of selective estrogen
receptor modulators used in breast cancer treatment and prevention. The objective of this study was
to determine whether or not insulin-like growth factor-I (IGF-1) and its
receptor (IGF-1R), has any role in the effect mechanism of TAM on the ovary.
Experimentally, animals were divided into three groups as control group (n=
20), low dose TAM treatment group (0.5 mg/mouse/day, n= 20) and high dose TAM
treatment group (1.5 mg/mouse/day, n= 20). TAM was injected 0.5 and 1.5
mg/mouse/day for 5 days. Ovarian sections were used to examine the general
structure by trichrome staining method and to determine IGF-1 and IGF-1R
expressions by immunohistochemical staining method. After the experiment, the
presence of atretic follicles and small cystic structures in the TAM-treated
animals was determined. Also, antral follicles and the corpus luteum were much
less in the high dose TAM group than in the control. TAM did not change the
expression of IGF-1 in granulosa cells, but increased the expression of IGF-1R.
In TAM groups, IGF-1 and IGF-1R expression were increased in oocytes of
follicles and in interstitial cells depending on TAM doses. However, while
IGF-1 expression was unchanged in the corpus luteum, decreased in treatment
group. TAM generally stimulated IGF-1 and IGF-1R expression in a dose-dependent
manner. The results suggest that IGF-1 signaling pathway is involved in the
mechanism of action of TAM on the ovary. We may assert that it may be useful to
use IGF-1 signaling pathway regulators to adjust the effects of TAM on the
ovary.

Anahtar Kelimeler

: IGF-1, IGF-1R, mouse, ovary, reproduction, tamoxifen

Kaynakça

  • 1. Akduman AT, Özerkan K, Zik B, et al (2014): Effect of tamoxifen on ovarian reserve: A randomized controlled assessor-blind trial in a mouse model. J Turk Ger Gynecol Assoc, 15, 228-232.
  • 2. Akkaya OO, Altunbas K, Yagcı A (2017): Effects of methoxychlor on IGF-1 signaling pathway in rat ovary. Biotech Histochem, 92, 230-242.
  • 3. Armstrong DG, Gutierrez CG, Baxter G, et al (2000): Expression of mRNA encoding IGF-1, IGF-1I and type 1 IGF receptor in bovine ovarian follicles. J Endocrinol, 165, 101-113.
  • 4. Armstrong DG, Webb R (1997): Ovarian follicular dominance: the role of intraovarian growth factors and novel proteins. Rev Reprod, 2, 139–146.
  • 5. Baumgarten SC, Convissar SM, Fierro MA, et al (2014): IGF1R signaling is necessary for FSH-induced activation of AKT and differentiation of human cumulus granulosa cells. J Clin Endocrinol Metab, 99, 2995-3004.
  • 6. Cara JF, Rosenfield RL (1988): Insulin-like growth factor I and ınsulin potentiate luteinizing hormone-ınduced androgen synthesis by rat ovarian thecal-interstitial cells. Endocrinology, 123, 733-739.
  • 7. Cohen I, Figer A, Tepper R, et al (1999): Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen treated and nontreated breast cancer patients. Gynecol Oncol, 72, 202-207.
  • 8. Crossman G (1937): A modification of Mallory’s connective tissue stain with a discussion of the principles involved. Anat Rec, 69, 33-38.
  • 9. Cruickshank J, Grossman DI, Peng RK, et al (2005): Spatial distribution of growth hormone receptor, insulin-like growth factor-I receptor and apoptotic chondrocytes during growth plate development. J Endocrinol, 184, 543-553.
  • 10. Ergin K, Gursoy E, Baġımoğlu-Koca Y, et al (2008): Immunohistochemical detection of insulin-like growth factor-I, transforming growth factor-b2, basic fibroblast growth factor and epidermal growth factor-receptor expression in developing rat ovary. Cytokine, 43, 209-214.
  • 11. Fu Z, Noguchi T, Kato H (2001): Vitamin a deficiency reduces insulin-like growth factor (IGF)-I gene expression and increases IGF-1 receptor and insulin receptor gene expression in tissues of japanese quail (coturnix coturnix japonica). J Nutr, 131, 1189-1194.
  • 12. Guthrie HD, Garrett WM, Cooper BS (1998): Follicle-stimulating hormone and insulin-like growth factor-I attenuate apoptosis in cultured porcine granulosa cells. Biol Reprod, 58, 390-396.
  • 13. Higgins MJ, Baselga J (2011): Targeted therapies for breast cancer. J Clin Invest, 121, 3797-3803.
  • 14. Hu CL, Cowan RG, Harman RM, et al (2004): Cell cycle progression and activation of akt kinase are required for insulin-like growth factor I-mediated suppression of apoptosis in granulosa cells. Mol Endocrinol, 18, 326-338.
  • 15. Kwintkiewicz J, Giudice LC (2009): The interplay of insulin-like growth factors, gonadotropins, and endocrine disruptors in ovarian follicular development and function. Semin Reprod Med, 27, 43-51.
  • 16. Luigi LD, Conti FG, Casini A (1997): Growth hormone and insulin-like growth factor I responses to moderate submaximal acute physical exercise in man: effects of octreotide, a somatostatin analogue, administration. Int J Sports Med, 18, 257-263.
  • 17. Macgregor JI, Jordan C (1998): Basic guide to the mechanisms of antiestrogens. Pharmacol Rev, 50, 151-196.
  • 18. Mahran YF, El-Demerdash E, Nada AS, et al (2013): Insights into the protective mechanisms of tamoxifen in radiotherapy-induced ovarian follicular loss: Impact on insulin-like growth factor 1. Endocrinology, 154, 3888-3899.
  • 19. Mazerbourg S, Bondy CA, Zhou J, et al (2003): The insulin-like growth factor system: a key determinant role in the growth and selection of ovarian follicles? a comparative species study. Reprod Domest Anim, 38, 247-258.
  • 20. Monget P, Fabre S, Mulsant P, et al (2002): Regulation of ovarian folliculogenesis by IGF and BMP system in domestic animals. Domest Anim Endocrinol, 23, 139-154.
  • 21. Monniaux D, Pisselet C (1992): Control of proliferation and differentiation of ovine granulosa cells by insulin-like growth factor-I and follicle-stimulating hormone in vitro. Biol Reprod, 46, 109-119.
  • 22. Mourits MJE, Vries EGE, Willemse PHB, et al (1999): Ovarian cysts in women receiving tamoxifen for breast cancer. Br J Cancer, 79, 1761-1764.
  • 23. O'Regan RM, Cisneros A, England GM, et al (1998): Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. J Natl Cancer Inst, 90, 1552-1558.
  • 24. Pasqualini JR, Sumida C, Giambiagi N (1998): Pharmacodynamic and biological effects of anti-estrogens in different models. J Steroid Biochem, 31, 613-643.
  • 25. Perks CM, Peters AR, Wathes DC (1999): Follicular and luteal expression of insulin-like growth factors I and II and the type 1 IGF receptor in the bovine ovary. J Reprod Fertil, 116, 157-165.
  • 26. Pollak MN, Huynh HT, Lefebvre SP (1992): Tamoxifen reduces serum insulin-like growth factor I (IGF-1). Breast Cancer Res Treat, 22, 91-100.
  • 27. Qu J, Godin PA, Nisolle M, et al (2000): Expression of receptors for insulin-like growth factor-I and transforming growth factor-β in human follicles. Mol Hum Reprod, 6, 137-145.
  • 28. Quirk SM, Cowan RG, Harman RM, et al (2004): Ovarian follicular growth and atresia: the relationship between cell proliferation and survival. J Anim Sci, 82, 40-52.
  • 29. Ramachandran C, Khatib Z, Petkarou A, et al (2004): Tamoxifen modulation of etoposide cytotoxicity involves inhibition of protein kinase C activity and insulin-like growth factor II expression in brain tumor cells. J Neurooncol, 67, 19-28.
  • 30. Rzepczynska IJ, Piotrowski PC, Wong DH, et al (2009): Role of isoprenylation in Simvastatin-Induced inhibition of ovarian theca-interstitial growth in the rat. Biol Reprod, 81, 850-855.
  • 31. Sherman BM, Chapler FK, Crickard K, et al (1979): Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women. J Clin Invest, 64, 398-404.
  • 32. Shushan A, Peretz T, Uziely B, et al (1996): Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer. Am J Obstet Gynecol, 174, 141-144.
  • 33. Spicer LJ, Chamberlain CS (1998): Influence of cortisol on insulin- and insulin-like growth factor 1 (IGF-1)-induced steroid production and on IGF-1 receptors in cultured bovine granulosa cells and thecal cells. Endocrine, 9, 153-161.
  • 34. Terada S, Uchide K, Suzuki N (1993): A follicular cyst during tamoksifen therapy in a premenopausal breast cancer woman. Gynecol Obstet Invest, 35, 62-64.
  • 35. Thissen JP, Ketelslegers JM, Underwood LE (1994): Nutritional regulation of the insulin-like growth factors. Endocr Rev, 15, 80-163.
  • 36. Ting AY, Kimler BF, Fabian CJ, et al (2008): Tamoxifen prevents premalignant changes of breast but not ovarian cancer in rats at high risk for both diseases. Cancer Prev Res, (Phila) 1, 546-553.
  • 37. Ting AY, Petroff BK (2010): Tamoxifen decreases ovarian follicular loss from experimental toxicant DMBA and chemotherapy agents cyclophosphamide and doxorubicin in the rat. J Assist Reprod Genet, 27, 591-597.
  • 38. Toda K, Miyaura C, Okada T, et al (2002): Dietary bisphenol a prevents ovarian degeneration and bone loss in female mice lacking the aromatase gene (Cyp19). Eur J Biochem, 269, 2214-2222.
  • 39. Tsujioka S, Ban Y, Wise LD, et al (2009): Collaborative work on evaluation of ovarian toxicity. 3) Effects of 2- or 4- week repeated dose toxicity and fertility studies with tamoksifen in female rats. J Toxicol Sci, 34, 43-51.
  • 40. Tucker MJ, Adam HK, Patterson JS (1984): Tamoxifen. 125-161. In: DR Laurence, AEM McLean, M Wetherall (Eds), Safety Testing of New Drugs, Laboratory Predictions and Clinical Performance. Academic. Press, London.
  • 41. Wandji SA, Wood TL, Crawford J, et al (1998): Expression of mouse ovarian insulin growth factor system components during follicular development and atresia. Endocrinology, 139, 5205-5214.
  • 42. Werner H, Shen-Orr Z, Stannard B, et al (1990): Experimental diabetes ıncreases ınsulinlike growth factor I and II receptor concentration and gene expression in kidney. Diabetes, 39, 1490-1497.
  • 43. Zhou J, Chin E, Bondy C (1991): Cellular pattern of insulin-like factor-I (IGF-1) and IGF-1 receptor gene expression in the developing and mature ovarian follicle. Endocrinology, 129, 3281-3288.
  • 44. Zhou P, Baumgarten SC, Wu Y, et al (2013): IGF-1 signaling is essential for FSH stimulation of AKT and steroidogenic genes in granulosa cells. Mol Endocrinol, 27, 511-523.

Ayrıntılar

Birincil Dil İngilizce
Konular Veteriner Cerrahi
Bölüm Makaleler
Yazarlar

Ender Deniz ASMAZ

0000-0001-6468-8535
Türkiye

Berrin ZIK

0000-0002-1053-6250
Türkiye

Yayımlanma Tarihi 9 Eylül 2019
Yayınlandığı Sayı Yıl 2019Cilt: 66 Sayı: 4

Kaynak Göster

Bibtex @araştırma makalesi { auvfd498411, journal = {Ankara Üniversitesi Veteriner Fakültesi Dergisi}, issn = {1300-0861}, eissn = {1308-2817}, address = {}, publisher = {Ankara Üniversitesi}, year = {2019}, volume = {66}, number = {4}, pages = {343 - 350}, doi = {10.33988/auvfd.498411}, title = {The effect of tamoxifen on IGF signaling pathway in the mouse ovary}, key = {cite}, author = {Asmaz, Ender Deniz and Zık, Berrin} }
APA Asmaz, E. D. & Zık, B. (2019). The effect of tamoxifen on IGF signaling pathway in the mouse ovary . Ankara Üniversitesi Veteriner Fakültesi Dergisi , 66 (4) , 343-350 . DOI: 10.33988/auvfd.498411
MLA Asmaz, E. D. , Zık, B. "The effect of tamoxifen on IGF signaling pathway in the mouse ovary" . Ankara Üniversitesi Veteriner Fakültesi Dergisi 66 (2019 ): 343-350 <http://vetjournal.ankara.edu.tr/tr/pub/issue/47708/498411>
Chicago Asmaz, E. D. , Zık, B. "The effect of tamoxifen on IGF signaling pathway in the mouse ovary". Ankara Üniversitesi Veteriner Fakültesi Dergisi 66 (2019 ): 343-350
RIS TY - JOUR T1 - The effect of tamoxifen on IGF signaling pathway in the mouse ovary AU - Ender DenizAsmaz, BerrinZık Y1 - 2019 PY - 2019 N1 - doi: 10.33988/auvfd.498411 DO - 10.33988/auvfd.498411 T2 - Ankara Üniversitesi Veteriner Fakültesi Dergisi JF - Journal JO - JOR SP - 343 EP - 350 VL - 66 IS - 4 SN - 1300-0861-1308-2817 M3 - doi: 10.33988/auvfd.498411 UR - https://doi.org/10.33988/auvfd.498411 Y2 - 2019 ER -
EndNote %0 Ankara Üniversitesi Veteriner Fakültesi Dergisi The effect of tamoxifen on IGF signaling pathway in the mouse ovary %A Ender Deniz Asmaz , Berrin Zık %T The effect of tamoxifen on IGF signaling pathway in the mouse ovary %D 2019 %J Ankara Üniversitesi Veteriner Fakültesi Dergisi %P 1300-0861-1308-2817 %V 66 %N 4 %R doi: 10.33988/auvfd.498411 %U 10.33988/auvfd.498411
ISNAD Asmaz, Ender Deniz , Zık, Berrin . "The effect of tamoxifen on IGF signaling pathway in the mouse ovary". Ankara Üniversitesi Veteriner Fakültesi Dergisi 66 / 4 (Eylül 2019): 343-350 . https://doi.org/10.33988/auvfd.498411
AMA Asmaz E. D. , Zık B. The effect of tamoxifen on IGF signaling pathway in the mouse ovary. Ankara Univ Vet Fak Derg. 2019; 66(4): 343-350.
Vancouver Asmaz E. D. , Zık B. The effect of tamoxifen on IGF signaling pathway in the mouse ovary. Ankara Üniversitesi Veteriner Fakültesi Dergisi. 2019; 66(4): 343-350.
IEEE E. D. Asmaz ve B. Zık , "The effect of tamoxifen on IGF signaling pathway in the mouse ovary", Ankara Üniversitesi Veteriner Fakültesi Dergisi, c. 66, sayı. 4, ss. 343-350, Eyl. 2019, doi:10.33988/auvfd.498411